4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶

生物活性靶点体外研究体内研究 4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶试剂级价格

CAS号:330786-25-9
英文名:PCI 29732
中文名:4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶
CBNumber:CB12668434
分子式:C22H21N5O
分子量:371.43
MOL File:330786-25-9.mol

4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶化学性质

沸点 :599.6±50.0 °C(Predicted)
密度 :1.36±0.1 g/cm3(Predicted)
储存条件 :Store at -20°C
溶解度 :DMF: 20 mg/ml; DMF:PBS (pH 7.2) (1:2): 0.3 mg/ml; DMSO: 10 mg/ml; Ethanol: 5 mg/ml
酸度系数(pKa) :4.24±0.30(Predicted)
形态 :Powder
颜色 :White to off-white

4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶性质、用途与生产工艺

生物活性 PCI 29732是一种选择性的、不可逆的Btk抑制剂，IC50为0.5 nM。
靶点
Target Value
BTK
(Cell-free assay) 0.5 nM
BLK
(Cell-free assay) 0.5 nM
Bmx
(Cell-free assay) 0.8 nM
EGFR
(Cell-free assay) 5.6 nM
YES
(Cell-free assay) 6.5 nM
体外研究

PCI29732 shows cytotoxicity in different cells. The IC ₅₀ values are 7.94 μM for S1, 7.79 μM for S1-MI-80, 6.55 μM for H460, 6.34 μM for H460/MX20, 6.14 μM for KB, 6.02 μM for KBv200, 12.45 μM for HEK293/pcDNA3, 14.58 μM for HEK293-ABCG2-482-R2, and 13.24 μM for HEK293-ABCG2-482-T7 cells.
PCI-29732 blocks the transcriptional up-regulation of a panel of B-cell activation genes in human CD20+ B cells stimulated at the B-cell antigen receptor (BCR).

体内研究

PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents.
PCI 29732 (20 mg/kg; p.o.; every 3 d × 5 times) enhances the anticancer efficacy of Topotecan in the H460/MX20 cell xenograft nude mice model.

Animal Model:	5-6 weeks old athymic nude mice (bearing H460/MX20 cells)
Dosage:	20 mg/kg (combination with Topotecan; every 3 d × 5 times, i.p., 3 mg/kg; topotecan was given 1 h after PCI29732 administration)
Administration:	P.o.; every 3 d × 5 times
Result:	Significant reductions in tumor weight and volume were observed in the group treated with PCI29732 in combination with Topotecan.